Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura

Israel Medical Association Journal

Volumn 13, Issue 7, 2011, Pages 398-401

  Stein, Gideon Y ^a   Blickstein, Dorit ^a   Orlin, Jerome ^a   Sarig, Galit ^b   Inbal, Aida ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

ADAMTS13; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADULT; ANTIBODY DETECTION; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; EPIDURAL HEMATOMA; FEMALE; FEVER; HEMATURIA; HEMIPARESIS; HUMAN; KIDNEY FAILURE; MALE; NEPHRITIS; PLASMAPHERESIS; PURPURA; RELAPSE; REMISSION; SEIZURE; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 79960696106     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
2. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
3. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombo-cytopenic purpura. Blood 2008; 112: 11-18.
4. Cataland SR, Wu HM. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. Expert Opin Pharmacother 2007; 8: 437-44.
5. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
6. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
7. Elliott MA, Heit JA, Pruthi RK, Gastineau DA, Winters JL, Hook CC. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009; 83: 365-72.
8. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009; 84: 418-21.
9. Rabkin Y, Fradin Z, Zeidman A, Schwartz A, Cohen A, Mittelman M. Chronic relapsing thrombocytopenic purpura with severe neurological manifestations and full recovery. Int J Hematol 2000; 71: 184-7.
10. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 2004; 80: 94-6.
11. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
12. Colson P, Gerolami R, Moreau J, Borentain P, Brouqui P. Concurrent autochthonous acute hepatitis E and hepatitis B reverse seroconversion in an HIV-1-infected patient: one virus may hide another. Int J Infect Dis 2009; 14: e357.
13. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2009; 89: 255-62.
14. Dabrow MB, Wilkins JC. Hematologic emergencies. Management of hyper leukocytic syndrome, DIC, and thrombotic thrombocytopenic purpura. Postgrad Med 1993; 93: 193-4, 197-9, 202.
15. Moake JL, Rudy CK, Troll JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985; 20: 73-9.
16. Thompson HW, McCarthy LJ. Thrombotic thrombocytopenic purpura. Potential benefit of splenectomy after plasma exchange. Arch Intern Med 1983; 143: 2117-19.
17. Van Gool S, Brock P, Van Laer P, Van Damme-Lombaerts R, Proesmans W, Casteels-Van Daele M. Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine. Eur J Pediatr 1994; 153: 517-19.
18. Kolodziej M. Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura. Am J Med Sci 1993; 305: 101-2.
19. Boumans MJ, Tak PP. Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther 2009; 11: 134.
20. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-9.
21. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
22. Verbeke L, Delforge M, Dierickx D. Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2010; 21: 3-10.
23. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7.
24. George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood 2010; 116: 4060-9.
25. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-91.